Literature DB >> 20805506

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Olaf Merkel1, Frank Hamacher, Daniela Laimer, Eveline Sifft, Zlatko Trajanoski, Marcel Scheideler, Gerda Egger, Melanie R Hassler, Christiane Thallinger, Ana Schmatz, Suzanne D Turner, Richard Greil, Lukas Kenner.   

Abstract

Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma. Since that time, many studies have set out to identify the mechanisms used by aberrant ALK toward tumorigenesis. We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK. Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL. Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL. Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins. Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models. In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805506      PMCID: PMC2941277          DOI: 10.1073/pnas.1009719107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Francisco Vega; L Jeffrey Medeiros; Vasiliki Leventaki; Coralyn Atwell; Jeong Hee Cho-Vega; Ling Tian; Francois-Xavier Claret; George Z Rassidakis
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

Review 2.  New and old functions of STAT3: a pivotal target for individualized treatment of cancer.

Authors:  Giorgio Inghirami; Roberto Chiarle; William J Simmons; Roberto Piva; Karni Schlessinger; David E Levy
Journal:  Cell Cycle       Date:  2005-09-30       Impact factor: 4.534

3.  Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice.

Authors:  Stefan Costinean; Nicola Zanesi; Yuri Pekarsky; Esmerina Tili; Stefano Volinia; Nyla Heerema; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

4.  Malignant histiocytosis: a specific t(2;5)(p23;q35) translocation? Review of the literature.

Authors:  E Benz-Lemoine; A Brizard; J L Huret; P Babin; F Guilhot; D Couet; J Tanzer
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

5.  Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.

Authors:  M U Kuefer; A T Look; K Pulford; F G Behm; P K Pattengale; D Y Mason; S W Morris
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

6.  CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

Authors:  D Y Mason; C Bastard; R Rimokh; N Dastugue; J L Huret; U Kristoffersson; J P Magaud; C Nezelof; H Tilly; J P Vannier
Journal:  Br J Haematol       Date:  1990-02       Impact factor: 6.998

7.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

8.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

9.  The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts.

Authors:  A Wellmann; V Doseeva; W Butscher; M Raffeld; P Fukushima; M Stetler-Stevenson; K Gardner
Journal:  FASEB J       Date:  1997-10       Impact factor: 5.191

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

View more
  51 in total

Review 1.  Update: peripheral T-cell lymphomas.

Authors:  Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

Review 2.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Authors:  Gaetano Santulli; Hana Totary-Jain
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

3.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Authors:  Elisa Spaccarotella; Elisa Pellegrino; Manuela Ferracin; Cristina Ferreri; Giuditta Cuccuru; Cuiling Liu; Javeed Iqbal; Daniela Cantarella; Riccardo Taulli; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Massimo Negrini; Wing C Chan; Giorgio Inghirami; Roberto Piva
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

Review 4.  MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development.

Authors:  Katie Podshivalova; Daniel R Salomon
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 6.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

7.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

8.  Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Authors:  Giovanni Nassa; Roberta Tarallo; Giorgio Giurato; Maria Rosaria De Filippo; Maria Ravo; Francesca Rizzo; Claudia Stellato; Concetta Ambrosino; Marc Baumann; Niina Lietzèn; Tuula A Nyman; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2014-02-13       Impact factor: 5.911

9.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

10.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.